Quarterly report · Q3
4272.TEDINET S100SQH6
Period2023-04-01 → 2023-12-31
Filed2024-02-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥149.8bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥198.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥153.6bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥19.1bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥7.5bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.0bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥4.2bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥21.6bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.8bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥15.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥15.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥351.3bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥322.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥331.4bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥91.4bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥67.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥259.9bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥255.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥255.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥49.6bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥48.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥17.06 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.68 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.36 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.62 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.57 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥17.04 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥89.33 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥90.6 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 73.7% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.9% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥130m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥130m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥5.9bn |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥40.9bn |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥40.7bn |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥129m |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥3.3bn |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥48.3bn |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥48.3bn |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥888m |
| jpcrp040300-q3r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥60.7bn |
| jpcrp040300-q3r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥60.7bn |
| jpcrp040300-q3r_E00836-000Mobility And Imaging Business Unitreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥5.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥149.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥149.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥130m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥10.0bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥122m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥122m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥5.6bn |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥51.8bn |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥51.6bn |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥122m |
| jpcrp040300-q3r_E00836-000Fine Chemicals Business Unitreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥9.5bn |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥47.2bn |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥47.2bn |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E00836-000Life Science Business Unitreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥8.5bn |
| jpcrp040300-q3r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥54.8bn |
| jpcrp040300-q3r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥54.8bn |
| jpcrp040300-q3r_E00836-000Mobility And Imaging Business Unitreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥6.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥153.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥153.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥122m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥24.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 387
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 122000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 122000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -122000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 54750000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 51756000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 47243000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 153750000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -122000000 | JPY |
| Net sales | Prior1YTDDuration | 153627000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 6752000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 9479000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 8476000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 24708000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -5645000000 | JPY |
| Operating income | Prior1YTDDuration | 19062000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 60709000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 40742000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 48301000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 149753000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 149753000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 129000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 130000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -130000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 60709000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 40872000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 48301000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 149883000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -130000000 | JPY |
| Net sales | CurrentYTDDuration | 149753000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 5861000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 3275000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 888000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10025000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -5913000000 | JPY |
| Operating income | CurrentYTDDuration | 4111000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-07 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第167期第３四半期(自 2023年10月１日 至 2023年12月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)日本化薬株式会社 | |
| Company name in english cover page | FilingDateInstant | NIPPON KAYAKU CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 涌元 厚宏 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区丸の内二丁目１番１号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |